The Motley Fool··Selena MaranjianResMed Eyes Growth Despite Healthcare Headwinds With Valuation Upside
ResMed trades at a 25% valuation discount despite 11% revenue growth and expanding digital health operations in 140+ countries, though Medicare reimbursement risks persist.
RMDstock valuationgrowth stocks